Silk Road Medical to Present at the Stifel 2020 Virtual Healthcare Conference
Silk Road Medical (Nasdaq: SILK) announced its participation in the Stifel 2020 Virtual Healthcare Conference on November 17, 2020, at 3:20 p.m. Eastern Time.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Silk Road Medical (Nasdaq: SILK) announced its participation in the Stifel 2020 Virtual Healthcare Conference on November 17, 2020, at 3:20 p.m. Eastern Time. The company aims to reduce stroke risks through its TransCarotid Artery Revascularization (TCAR) procedure, which addresses carotid artery blockages. Interested individuals can access the live or archived webcast of the presentation through the company's website. This event highlights Silk Road Medical's commitment to improving patient outcomes and enhancing clinical practices.
Details
News Market Reaction – SILK
The recorded move for SILK in the trading session of this news was +2.81%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SUNNYVALE, Calif., Nov. 04, 2020 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced the company will be participating in the upcoming Stifel 2020 Virtual Healthcare Conference.
Silk Road Medical’s management is scheduled to present on Tuesday, November 17, 2020 at 3:20 p.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation on the “Investors” section of the company’s website at: https://investors.silkroadmed.com/.
About Silk Road Medical
Silk Road Medical, Inc. (NASDAQ: SILK), is a medical device company located in Sunnyvale, California, that is focused on reducing the risk of stroke and its devastating impact. The company’s flagship procedure, TransCarotid Artery Revascularization (TCAR), is clinically proven to treat blockages in the carotid artery at risk of causing a stroke. For more information on how Silk Road Medical is delivering brighter patient outcomes through brighter clinical thinking, visit www.silkroadmed.com and connect on Twitter, LinkedIn and Facebook.
Investor Contact:
Lynn Lewis or Caroline Paul
Gilmartin Group
investors@silkroadmed.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.